Scancell Holdings plc engages in the discovery and development of novel monoclonal antibodies and vaccines for the treatment of cancer in the United Kingdom.
The last earnings update was 78 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Scancell Holdings. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Scancell Holdings's earnings available for a low price, and how does
this compare to other companies in the same industry?
Scancell Holdings is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Scancell Holdings is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Scancell Holdings's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Scancell Holdings's finances.
The net worth of a company is the difference between its assets and liabilities.
Scancell Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Scancell Holdings has no long term commitments.
This treemap shows a more detailed breakdown of
Scancell Holdings's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Scancell Holdings has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Clifford Holloway, also known as Cliff, BPharm, Ph.D., is the Chief Executive Officer of Scancell Holdings Plc since January 10, 2018. Dr. Holloway was the Chief Business and Operating Officer at Benitec Biopharma Limited since joining in August 24, 2016. Dr. Holloway served as the Vice President of Business Development for Products at Teva Pharmaceuticals Australia Pty Ltd. since January 24, 2006. He served as a Director at Newstar Ventures Ltd. Dr. Holloway served as Chief Executive Officer and Managing Director of Sienna Cancer Diagnostics Limited from November 05, 2015 to August 15, 2016 and Biosceptre International Limited. He served as the Chief Executive Officer and Managing Director at Immune System Therapeutics Limited. He served as Vice President Business Development at ASX listed biotechnology company Arana Therapeutics Limited. Dr. Holloway has held executive management and directorship positions within the Biopharmaceutical and ICT industries, resulting in dynamic career progression based on establishing international operations, monetising emerging technologies and restructuring of companies in the private and public sectors to improve commercial outcome. Dr. Holloway has direct experience in establishing and negotiating technology partnerships, IP licensing, asset acquisitions, royalty agreements, joint ventures, equity investments and company mergers and acquisitions. He has extensive international experience in biopharmaceutical and healthcare related technologies with a focus on commercialization and product development. Dr. Holloway obtained a Bachelor of Pharmacy and a Ph.D in Medicinal Chemistry from the University of Nottingham.
Insufficient data for Cliff to compare compensation growth.
Cliff's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Scancell Holdings management team is less than 2 years, this suggests a new team.
Chief Executive Officer
Chief Scientific Officer & Director
Development Director & Director
Director of Finance & Administration
Head of Research
Head of Manufacturing
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Scancell Holdings board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Scancell Holdings plc engages in the discovery and development of novel monoclonal antibodies and vaccines for the treatment of cancer in the United Kingdom. The company’s products include SCIB1, a plasmid DNA vaccine, which is in Phase I/II clinical trials for the treatment of melanoma; SCIB2 to treat lung cancer antigen; and Modi-1, which is in the pre-clinical development to treat triple negative breast cancer, ovarian cancer, and sarcoma. It is also developing Modi-2, a moditope program that is in pre-clinical development to address multiple cancer indications. Scancell Holdings plc has a research collaboration agreement with BioNTech to develop T-cell therapies for the treatment of cancer. It also has a licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA’s AMPLIVANT adjuvant technology for the manufacturing, development, and commercialization of Modi-1. The company was incorporated in 2008 and is based in Oxford, the United Kingdom.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.